Skip to content
DataLookout
Menu

NCT05024929

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion moved earlier from Feb 1, 2031 to Jul 2027
    • Enrollment closed, study ongoing
    • Study completion moved earlier from Feb 1, 2033 to Jul 2028
  2. Minor Site contacts updated at 1 of 9 sitesv11
  3. Minor Site contacts updated at 1 of 9 sitesv10
  4. Minor Study sites: 5 to 9v9
  5. Minor Site contacts updated at 1 of 5 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Eligibility criteria expanded, about 17 words
    • Site details revised at 4 of 5 sites
    v7
  2. Notable Eligibility criteria expanded, about 83 wordsv6 Show 5 more changesShow less
    • Study sites: 1 to 5
    • Study description expanded, about 18 words
    • Study title revised
    • Study arms: 0 to 2
    • Collaborators expanded, about 5 words
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 1, 2022 to Jul 16, 2021
    • Site details revised
    v5
  4. Notable Start date: Dec 1, 2021 to Feb 1, 2022v4
  5. Notable Start date: Oct 1, 2021 to Dec 1, 2021v3
  6. Notable Start date: Sep 1, 2021 to Oct 1, 2021v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy
Timeframe: up to 5 years

Arms and interventions

Prospective Cohort

Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial

Data Sharing Cohort

Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing

Procedures: Whole body scan

Sites

8 sites in 2 countries

United States 7, Australia 1